nodes	percent_of_prediction	percent_of_DWPC	metapath
Loxapine—CHRM3—muscle of abdomen—muscle cancer	0.059	0.12	CbGeAlD
Loxapine—HTR5A—head—muscle cancer	0.0266	0.0541	CbGeAlD
Loxapine—HRH4—bone marrow—muscle cancer	0.022	0.0446	CbGeAlD
Loxapine—Ileus paralytic—Vincristine—muscle cancer	0.0204	0.0403	CcSEcCtD
Loxapine—HTR2A—hindlimb—muscle cancer	0.0179	0.0364	CbGeAlD
Loxapine—HTR2A—appendage—muscle cancer	0.0154	0.0312	CbGeAlD
Loxapine—Throat tightness—Etoposide—muscle cancer	0.0146	0.0288	CcSEcCtD
Loxapine—DRD4—testis—muscle cancer	0.0127	0.0259	CbGeAlD
Loxapine—HTR1E—head—muscle cancer	0.0114	0.0231	CbGeAlD
Loxapine—HRH2—cardiac atrium—muscle cancer	0.0109	0.0222	CbGeAlD
Loxapine—Numbness—Vincristine—muscle cancer	0.0107	0.021	CcSEcCtD
Loxapine—ADRA1B—renal system—muscle cancer	0.0106	0.0216	CbGeAlD
Loxapine—Sensory loss—Vincristine—muscle cancer	0.0102	0.0201	CcSEcCtD
Loxapine—CHRM4—head—muscle cancer	0.00997	0.0202	CbGeAlD
Loxapine—CHRM4—testis—muscle cancer	0.00963	0.0196	CbGeAlD
Loxapine—DRD3—head—muscle cancer	0.00927	0.0188	CbGeAlD
Loxapine—Gait disturbance—Vincristine—muscle cancer	0.00906	0.0178	CcSEcCtD
Loxapine—HTR6—head—muscle cancer	0.00892	0.0181	CbGeAlD
Loxapine—DRD5—head—muscle cancer	0.00869	0.0176	CbGeAlD
Loxapine—Numbness—Etoposide—muscle cancer	0.00864	0.017	CcSEcCtD
Loxapine—Sensory loss—Etoposide—muscle cancer	0.00826	0.0163	CcSEcCtD
Loxapine—HRH2—head—muscle cancer	0.00816	0.0166	CbGeAlD
Loxapine—Chest discomfort—Etoposide—muscle cancer	0.00809	0.0159	CcSEcCtD
Loxapine—CHRM5—head—muscle cancer	0.00779	0.0158	CbGeAlD
Loxapine—ADRA1B—head—muscle cancer	0.00712	0.0145	CbGeAlD
Loxapine—ADRB1—cardiac atrium—muscle cancer	0.00677	0.0138	CbGeAlD
Loxapine—CHRM3—smooth muscle tissue—muscle cancer	0.00677	0.0137	CbGeAlD
Loxapine—DRD1—head—muscle cancer	0.00664	0.0135	CbGeAlD
Loxapine—CHRM3—renal system—muscle cancer	0.00651	0.0132	CbGeAlD
Loxapine—HTR1A—renal system—muscle cancer	0.00649	0.0132	CbGeAlD
Loxapine—HTR7—smooth muscle tissue—muscle cancer	0.00644	0.0131	CbGeAlD
Loxapine—HTR3A—head—muscle cancer	0.00641	0.013	CbGeAlD
Loxapine—Dysphagia—Dactinomycin—muscle cancer	0.00621	0.0122	CcSEcCtD
Loxapine—HTR7—renal system—muscle cancer	0.0062	0.0126	CbGeAlD
Loxapine—Urinary retention—Vincristine—muscle cancer	0.0061	0.012	CcSEcCtD
Loxapine—ADRA1A—renal system—muscle cancer	0.00598	0.0121	CbGeAlD
Loxapine—ADRA2C—renal system—muscle cancer	0.0057	0.0116	CbGeAlD
Loxapine—Seborrhoeic dermatitis—Doxorubicin—muscle cancer	0.00545	0.0107	CcSEcCtD
Loxapine—HTR1B—head—muscle cancer	0.00538	0.0109	CbGeAlD
Loxapine—CHRM2—head—muscle cancer	0.00535	0.0109	CbGeAlD
Loxapine—SLC6A3—head—muscle cancer	0.00534	0.0108	CbGeAlD
Loxapine—HTR1D—head—muscle cancer	0.00521	0.0106	CbGeAlD
Loxapine—Agranulocytosis—Dactinomycin—muscle cancer	0.00516	0.0102	CcSEcCtD
Loxapine—HTR2C—head—muscle cancer	0.00516	0.0105	CbGeAlD
Loxapine—SLC6A3—testis—muscle cancer	0.00515	0.0105	CbGeAlD
Loxapine—HTR2A—embryo—muscle cancer	0.00511	0.0104	CbGeAlD
Loxapine—ADRA2C—cardiac atrium—muscle cancer	0.0051	0.0104	CbGeAlD
Loxapine—Photosensitivity reaction—Vincristine—muscle cancer	0.00506	0.00997	CcSEcCtD
Loxapine—ADRB1—head—muscle cancer	0.00506	0.0103	CbGeAlD
Loxapine—Weight decreased—Vincristine—muscle cancer	0.00502	0.00988	CcSEcCtD
Loxapine—Hepatitis—Dactinomycin—muscle cancer	0.00497	0.00979	CcSEcCtD
Loxapine—SLC6A4—head—muscle cancer	0.00489	0.00993	CbGeAlD
Loxapine—CHRM1—head—muscle cancer	0.00487	0.00989	CbGeAlD
Loxapine—HTR7—tendon—muscle cancer	0.00484	0.00983	CbGeAlD
Loxapine—HRH1—smooth muscle tissue—muscle cancer	0.00481	0.00977	CbGeAlD
Loxapine—Dysarthria—Methotrexate—muscle cancer	0.00453	0.00893	CcSEcCtD
Loxapine—Dysphagia—Etoposide—muscle cancer	0.00449	0.00885	CcSEcCtD
Loxapine—ADRA2C—tendon—muscle cancer	0.00445	0.00903	CbGeAlD
Loxapine—Bronchospasm—Etoposide—muscle cancer	0.00442	0.00871	CcSEcCtD
Loxapine—Hypoaesthesia—Vincristine—muscle cancer	0.00442	0.0087	CcSEcCtD
Loxapine—Liver injury—Doxorubicin—muscle cancer	0.00441	0.00869	CcSEcCtD
Loxapine—Alopecia—Dactinomycin—muscle cancer	0.00439	0.00865	CcSEcCtD
Loxapine—CHRM3—head—muscle cancer	0.00436	0.00885	CbGeAlD
Loxapine—HTR1A—head—muscle cancer	0.00434	0.00881	CbGeAlD
Loxapine—SLC6A2—head—muscle cancer	0.0043	0.00874	CbGeAlD
Loxapine—Amenorrhoea—Doxorubicin—muscle cancer	0.00423	0.00833	CcSEcCtD
Loxapine—CHRM3—testis—muscle cancer	0.00421	0.00855	CbGeAlD
Loxapine—SLC6A2—testis—muscle cancer	0.00416	0.00844	CbGeAlD
Loxapine—HTR7—head—muscle cancer	0.00415	0.00842	CbGeAlD
Loxapine—ADRA2C—vagina—muscle cancer	0.00413	0.00838	CbGeAlD
Loxapine—ADRA2A—cardiac atrium—muscle cancer	0.00407	0.00827	CbGeAlD
Loxapine—Angiopathy—Vincristine—muscle cancer	0.00403	0.00793	CcSEcCtD
Loxapine—HTR2A—smooth muscle tissue—muscle cancer	0.00402	0.00816	CbGeAlD
Loxapine—HTR7—testis—muscle cancer	0.00401	0.00814	CbGeAlD
Loxapine—ADRA1A—head—muscle cancer	0.004	0.00813	CbGeAlD
Loxapine—Mediastinal disorder—Vincristine—muscle cancer	0.004	0.00788	CcSEcCtD
Loxapine—Dyskinesia—Doxorubicin—muscle cancer	0.00395	0.00779	CcSEcCtD
Loxapine—Renal failure—Etoposide—muscle cancer	0.00394	0.00776	CcSEcCtD
Loxapine—Dysarthria—Doxorubicin—muscle cancer	0.00393	0.00774	CcSEcCtD
Loxapine—DRD2—head—muscle cancer	0.00392	0.00796	CbGeAlD
Loxapine—Alopecia—Vincristine—muscle cancer	0.00392	0.00773	CcSEcCtD
Loxapine—Jaundice—Etoposide—muscle cancer	0.0039	0.00769	CcSEcCtD
Loxapine—Leukopenia—Dactinomycin—muscle cancer	0.00387	0.00763	CcSEcCtD
Loxapine—HTR2A—renal system—muscle cancer	0.00387	0.00785	CbGeAlD
Loxapine—Gynaecomastia—Methotrexate—muscle cancer	0.00384	0.00756	CcSEcCtD
Loxapine—ADRA2C—head—muscle cancer	0.00381	0.00774	CbGeAlD
Loxapine—Gait disturbance—Doxorubicin—muscle cancer	0.0038	0.0075	CcSEcCtD
Loxapine—DRD2—testis—muscle cancer	0.00379	0.00769	CbGeAlD
Loxapine—Agranulocytosis—Etoposide—muscle cancer	0.00374	0.00736	CcSEcCtD
Loxapine—Hepatocellular injury—Doxorubicin—muscle cancer	0.00371	0.00732	CcSEcCtD
Loxapine—ADRA2C—testis—muscle cancer	0.00368	0.00748	CbGeAlD
Loxapine—HRH1—tendon—muscle cancer	0.00361	0.00734	CbGeAlD
Loxapine—Salivary hypersecretion—Doxorubicin—muscle cancer	0.00361	0.00711	CcSEcCtD
Loxapine—Hypoaesthesia—Etoposide—muscle cancer	0.00358	0.00705	CcSEcCtD
Loxapine—Agitation—Vincristine—muscle cancer	0.00355	0.007	CcSEcCtD
Loxapine—ADRA2A—tendon—muscle cancer	0.00355	0.00721	CbGeAlD
Loxapine—Photosensitivity—Methotrexate—muscle cancer	0.00355	0.00699	CcSEcCtD
Loxapine—Oedema—Dactinomycin—muscle cancer	0.00353	0.00695	CcSEcCtD
Loxapine—Leukopenia—Vincristine—muscle cancer	0.00346	0.00681	CcSEcCtD
Loxapine—Thrombocytopenia—Dactinomycin—muscle cancer	0.00346	0.00681	CcSEcCtD
Loxapine—Dry eye—Doxorubicin—muscle cancer	0.00343	0.00676	CcSEcCtD
Loxapine—HRH1—vagina—muscle cancer	0.00335	0.00681	CbGeAlD
Loxapine—Convulsion—Vincristine—muscle cancer	0.00335	0.0066	CcSEcCtD
Loxapine—Hypertension—Vincristine—muscle cancer	0.00334	0.00657	CcSEcCtD
Loxapine—ADRA2A—vagina—muscle cancer	0.00329	0.00669	CbGeAlD
Loxapine—Angiopathy—Etoposide—muscle cancer	0.00326	0.00643	CcSEcCtD
Loxapine—Mediastinal disorder—Etoposide—muscle cancer	0.00324	0.00638	CcSEcCtD
Loxapine—Alopecia—Etoposide—muscle cancer	0.00318	0.00626	CcSEcCtD
Loxapine—Cerebrovascular accident—Methotrexate—muscle cancer	0.00318	0.00626	CcSEcCtD
Loxapine—Oedema—Vincristine—muscle cancer	0.00315	0.00621	CcSEcCtD
Loxapine—HRH1—head—muscle cancer	0.0031	0.00629	CbGeAlD
Loxapine—Nervous system disorder—Vincristine—muscle cancer	0.00309	0.00609	CcSEcCtD
Loxapine—Thrombocytopenia—Vincristine—muscle cancer	0.00309	0.00608	CcSEcCtD
Loxapine—Photosensitivity—Doxorubicin—muscle cancer	0.00307	0.00605	CcSEcCtD
Loxapine—Dysgeusia—Etoposide—muscle cancer	0.00306	0.00604	CcSEcCtD
Loxapine—Fatigue—Dactinomycin—muscle cancer	0.00304	0.006	CcSEcCtD
Loxapine—ADRA2A—head—muscle cancer	0.00304	0.00618	CbGeAlD
Loxapine—HTR2A—tendon—muscle cancer	0.00302	0.00613	CbGeAlD
Loxapine—Muscle spasms—Etoposide—muscle cancer	0.00301	0.00593	CcSEcCtD
Loxapine—HRH1—testis—muscle cancer	0.00299	0.00608	CbGeAlD
Loxapine—Hypotension—Vincristine—muscle cancer	0.00295	0.00581	CcSEcCtD
Loxapine—ADRA2A—testis—muscle cancer	0.00294	0.00597	CbGeAlD
Loxapine—Feeling abnormal—Dactinomycin—muscle cancer	0.00291	0.00573	CcSEcCtD
Loxapine—Insomnia—Vincristine—muscle cancer	0.00285	0.00562	CcSEcCtD
Loxapine—Paraesthesia—Vincristine—muscle cancer	0.00283	0.00558	CcSEcCtD
Loxapine—Leukopenia—Etoposide—muscle cancer	0.0028	0.00552	CcSEcCtD
Loxapine—HTR2A—vagina—muscle cancer	0.0028	0.00569	CbGeAlD
Loxapine—Loss of consciousness—Etoposide—muscle cancer	0.00275	0.00542	CcSEcCtD
Loxapine—Cerebrovascular accident—Doxorubicin—muscle cancer	0.00275	0.00542	CcSEcCtD
Loxapine—Cough—Etoposide—muscle cancer	0.00273	0.00538	CcSEcCtD
Loxapine—Gastrointestinal disorder—Vincristine—muscle cancer	0.00272	0.00536	CcSEcCtD
Loxapine—Fatigue—Vincristine—muscle cancer	0.00272	0.00536	CcSEcCtD
Loxapine—Convulsion—Etoposide—muscle cancer	0.00271	0.00534	CcSEcCtD
Loxapine—Hypertension—Etoposide—muscle cancer	0.0027	0.00532	CcSEcCtD
Loxapine—Constipation—Vincristine—muscle cancer	0.0027	0.00531	CcSEcCtD
Loxapine—Chest pain—Etoposide—muscle cancer	0.00266	0.00525	CcSEcCtD
Loxapine—Hypersensitivity—Dactinomycin—muscle cancer	0.0026	0.00512	CcSEcCtD
Loxapine—HTR2A—head—muscle cancer	0.00259	0.00525	CbGeAlD
Loxapine—Confusional state—Etoposide—muscle cancer	0.00258	0.00507	CcSEcCtD
Loxapine—Asthenia—Dactinomycin—muscle cancer	0.00253	0.00499	CcSEcCtD
Loxapine—Thrombocytopenia—Etoposide—muscle cancer	0.0025	0.00493	CcSEcCtD
Loxapine—HTR2A—testis—muscle cancer	0.0025	0.00507	CbGeAlD
Loxapine—Tachycardia—Etoposide—muscle cancer	0.00249	0.00491	CcSEcCtD
Loxapine—Orthostatic hypotension—Doxorubicin—muscle cancer	0.00246	0.00485	CcSEcCtD
Loxapine—Photosensitivity reaction—Methotrexate—muscle cancer	0.00246	0.00484	CcSEcCtD
Loxapine—Drowsiness—Methotrexate—muscle cancer	0.0024	0.00473	CcSEcCtD
Loxapine—Hypotension—Etoposide—muscle cancer	0.00239	0.0047	CcSEcCtD
Loxapine—Renal failure—Methotrexate—muscle cancer	0.00236	0.00465	CcSEcCtD
Loxapine—Dysphagia—Doxorubicin—muscle cancer	0.00233	0.00459	CcSEcCtD
Loxapine—Hypersensitivity—Vincristine—muscle cancer	0.00232	0.00458	CcSEcCtD
Loxapine—Paraesthesia—Etoposide—muscle cancer	0.00229	0.00452	CcSEcCtD
Loxapine—Dyspnoea—Etoposide—muscle cancer	0.00228	0.00449	CcSEcCtD
Loxapine—Somnolence—Etoposide—muscle cancer	0.00227	0.00447	CcSEcCtD
Loxapine—Asthenia—Vincristine—muscle cancer	0.00226	0.00446	CcSEcCtD
Loxapine—Vomiting—Dactinomycin—muscle cancer	0.00224	0.00442	CcSEcCtD
Loxapine—Agranulocytosis—Methotrexate—muscle cancer	0.00224	0.00441	CcSEcCtD
Loxapine—Rash—Dactinomycin—muscle cancer	0.00223	0.00438	CcSEcCtD
Loxapine—Gastrointestinal disorder—Etoposide—muscle cancer	0.00221	0.00434	CcSEcCtD
Loxapine—Fatigue—Etoposide—muscle cancer	0.0022	0.00434	CcSEcCtD
Loxapine—Constipation—Etoposide—muscle cancer	0.00218	0.0043	CcSEcCtD
Loxapine—Hepatitis—Methotrexate—muscle cancer	0.00215	0.00424	CcSEcCtD
Loxapine—Photosensitivity reaction—Doxorubicin—muscle cancer	0.00213	0.00419	CcSEcCtD
Loxapine—Weight increased—Doxorubicin—muscle cancer	0.00212	0.00418	CcSEcCtD
Loxapine—Weight decreased—Doxorubicin—muscle cancer	0.00211	0.00415	CcSEcCtD
Loxapine—Feeling abnormal—Etoposide—muscle cancer	0.0021	0.00415	CcSEcCtD
Loxapine—Nausea—Dactinomycin—muscle cancer	0.0021	0.00413	CcSEcCtD
Loxapine—Dizziness—Vincristine—muscle cancer	0.00209	0.00411	CcSEcCtD
Loxapine—Drowsiness—Doxorubicin—muscle cancer	0.00208	0.00409	CcSEcCtD
Loxapine—Renal failure—Doxorubicin—muscle cancer	0.00204	0.00402	CcSEcCtD
Loxapine—Jaundice—Doxorubicin—muscle cancer	0.00202	0.00399	CcSEcCtD
Loxapine—Vomiting—Vincristine—muscle cancer	0.002	0.00395	CcSEcCtD
Loxapine—Rash—Vincristine—muscle cancer	0.00199	0.00392	CcSEcCtD
Loxapine—Dermatitis—Vincristine—muscle cancer	0.00199	0.00391	CcSEcCtD
Loxapine—Headache—Vincristine—muscle cancer	0.00198	0.00389	CcSEcCtD
Loxapine—Angiopathy—Methotrexate—muscle cancer	0.00195	0.00385	CcSEcCtD
Loxapine—Mediastinal disorder—Methotrexate—muscle cancer	0.00194	0.00382	CcSEcCtD
Loxapine—Agranulocytosis—Doxorubicin—muscle cancer	0.00194	0.00382	CcSEcCtD
Loxapine—Alopecia—Methotrexate—muscle cancer	0.0019	0.00375	CcSEcCtD
Loxapine—Hypersensitivity—Etoposide—muscle cancer	0.00188	0.00371	CcSEcCtD
Loxapine—Nausea—Vincristine—muscle cancer	0.00187	0.00369	CcSEcCtD
Loxapine—Hepatitis—Doxorubicin—muscle cancer	0.00186	0.00367	CcSEcCtD
Loxapine—Hypoaesthesia—Doxorubicin—muscle cancer	0.00186	0.00366	CcSEcCtD
Loxapine—Dysgeusia—Methotrexate—muscle cancer	0.00184	0.00362	CcSEcCtD
Loxapine—Asthenia—Etoposide—muscle cancer	0.00183	0.00361	CcSEcCtD
Loxapine—Pruritus—Etoposide—muscle cancer	0.00181	0.00356	CcSEcCtD
Loxapine—Vision blurred—Methotrexate—muscle cancer	0.00177	0.00348	CcSEcCtD
Loxapine—Angiopathy—Doxorubicin—muscle cancer	0.00169	0.00333	CcSEcCtD
Loxapine—Dizziness—Etoposide—muscle cancer	0.00169	0.00333	CcSEcCtD
Loxapine—Mediastinal disorder—Doxorubicin—muscle cancer	0.00168	0.00331	CcSEcCtD
Loxapine—Leukopenia—Methotrexate—muscle cancer	0.00168	0.00331	CcSEcCtD
Loxapine—Alopecia—Doxorubicin—muscle cancer	0.00165	0.00325	CcSEcCtD
Loxapine—Cough—Methotrexate—muscle cancer	0.00164	0.00322	CcSEcCtD
Loxapine—Convulsion—Methotrexate—muscle cancer	0.00162	0.0032	CcSEcCtD
Loxapine—Vomiting—Etoposide—muscle cancer	0.00162	0.0032	CcSEcCtD
Loxapine—Rash—Etoposide—muscle cancer	0.00161	0.00317	CcSEcCtD
Loxapine—Dermatitis—Etoposide—muscle cancer	0.00161	0.00317	CcSEcCtD
Loxapine—Headache—Etoposide—muscle cancer	0.0016	0.00315	CcSEcCtD
Loxapine—Chest pain—Methotrexate—muscle cancer	0.0016	0.00314	CcSEcCtD
Loxapine—Tension—Doxorubicin—muscle cancer	0.00159	0.00314	CcSEcCtD
Loxapine—Dysgeusia—Doxorubicin—muscle cancer	0.00159	0.00313	CcSEcCtD
Loxapine—Muscle spasms—Doxorubicin—muscle cancer	0.00156	0.00307	CcSEcCtD
Loxapine—Confusional state—Methotrexate—muscle cancer	0.00154	0.00304	CcSEcCtD
Loxapine—Vision blurred—Doxorubicin—muscle cancer	0.00153	0.00301	CcSEcCtD
Loxapine—Nausea—Etoposide—muscle cancer	0.00152	0.00299	CcSEcCtD
Loxapine—Nervous system disorder—Methotrexate—muscle cancer	0.0015	0.00296	CcSEcCtD
Loxapine—Thrombocytopenia—Methotrexate—muscle cancer	0.0015	0.00295	CcSEcCtD
Loxapine—Agitation—Doxorubicin—muscle cancer	0.00149	0.00294	CcSEcCtD
Loxapine—Syncope—Doxorubicin—muscle cancer	0.00146	0.00287	CcSEcCtD
Loxapine—Leukopenia—Doxorubicin—muscle cancer	0.00145	0.00286	CcSEcCtD
Loxapine—Hypotension—Methotrexate—muscle cancer	0.00143	0.00282	CcSEcCtD
Loxapine—Loss of consciousness—Doxorubicin—muscle cancer	0.00143	0.00281	CcSEcCtD
Loxapine—Cough—Doxorubicin—muscle cancer	0.00142	0.00279	CcSEcCtD
Loxapine—Convulsion—Doxorubicin—muscle cancer	0.00141	0.00277	CcSEcCtD
Loxapine—Hypertension—Doxorubicin—muscle cancer	0.0014	0.00276	CcSEcCtD
Loxapine—Insomnia—Methotrexate—muscle cancer	0.00138	0.00273	CcSEcCtD
Loxapine—Chest pain—Doxorubicin—muscle cancer	0.00138	0.00272	CcSEcCtD
Loxapine—Paraesthesia—Methotrexate—muscle cancer	0.00137	0.00271	CcSEcCtD
Loxapine—Dyspnoea—Methotrexate—muscle cancer	0.00136	0.00269	CcSEcCtD
Loxapine—Somnolence—Methotrexate—muscle cancer	0.00136	0.00268	CcSEcCtD
Loxapine—Dry mouth—Doxorubicin—muscle cancer	0.00135	0.00266	CcSEcCtD
Loxapine—Confusional state—Doxorubicin—muscle cancer	0.00134	0.00263	CcSEcCtD
Loxapine—Oedema—Doxorubicin—muscle cancer	0.00132	0.00261	CcSEcCtD
Loxapine—Gastrointestinal disorder—Methotrexate—muscle cancer	0.00132	0.0026	CcSEcCtD
Loxapine—Fatigue—Methotrexate—muscle cancer	0.00132	0.0026	CcSEcCtD
Loxapine—Shock—Doxorubicin—muscle cancer	0.0013	0.00257	CcSEcCtD
Loxapine—Nervous system disorder—Doxorubicin—muscle cancer	0.0013	0.00256	CcSEcCtD
Loxapine—Thrombocytopenia—Doxorubicin—muscle cancer	0.0013	0.00256	CcSEcCtD
Loxapine—Tachycardia—Doxorubicin—muscle cancer	0.00129	0.00255	CcSEcCtD
Loxapine—Feeling abnormal—Methotrexate—muscle cancer	0.00126	0.00248	CcSEcCtD
Loxapine—Hypotension—Doxorubicin—muscle cancer	0.00124	0.00244	CcSEcCtD
Loxapine—Insomnia—Doxorubicin—muscle cancer	0.0012	0.00236	CcSEcCtD
Loxapine—Paraesthesia—Doxorubicin—muscle cancer	0.00119	0.00234	CcSEcCtD
Loxapine—Dyspnoea—Doxorubicin—muscle cancer	0.00118	0.00233	CcSEcCtD
Loxapine—Somnolence—Doxorubicin—muscle cancer	0.00118	0.00232	CcSEcCtD
Loxapine—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.00114	0.00225	CcSEcCtD
Loxapine—Fatigue—Doxorubicin—muscle cancer	0.00114	0.00225	CcSEcCtD
Loxapine—Constipation—Doxorubicin—muscle cancer	0.00113	0.00223	CcSEcCtD
Loxapine—Hypersensitivity—Methotrexate—muscle cancer	0.00113	0.00222	CcSEcCtD
Loxapine—Asthenia—Methotrexate—muscle cancer	0.0011	0.00216	CcSEcCtD
Loxapine—Feeling abnormal—Doxorubicin—muscle cancer	0.00109	0.00215	CcSEcCtD
Loxapine—Pruritus—Methotrexate—muscle cancer	0.00108	0.00213	CcSEcCtD
Loxapine—Dizziness—Methotrexate—muscle cancer	0.00101	0.00199	CcSEcCtD
Loxapine—Hypersensitivity—Doxorubicin—muscle cancer	0.000976	0.00192	CcSEcCtD
Loxapine—Vomiting—Methotrexate—muscle cancer	0.000973	0.00192	CcSEcCtD
Loxapine—Rash—Methotrexate—muscle cancer	0.000965	0.0019	CcSEcCtD
Loxapine—Dermatitis—Methotrexate—muscle cancer	0.000964	0.0019	CcSEcCtD
Loxapine—Headache—Methotrexate—muscle cancer	0.000958	0.00189	CcSEcCtD
Loxapine—Asthenia—Doxorubicin—muscle cancer	0.00095	0.00187	CcSEcCtD
Loxapine—Pruritus—Doxorubicin—muscle cancer	0.000937	0.00185	CcSEcCtD
Loxapine—Nausea—Methotrexate—muscle cancer	0.000909	0.00179	CcSEcCtD
Loxapine—Dizziness—Doxorubicin—muscle cancer	0.000876	0.00173	CcSEcCtD
Loxapine—Vomiting—Doxorubicin—muscle cancer	0.000842	0.00166	CcSEcCtD
Loxapine—Rash—Doxorubicin—muscle cancer	0.000835	0.00165	CcSEcCtD
Loxapine—Dermatitis—Doxorubicin—muscle cancer	0.000835	0.00164	CcSEcCtD
Loxapine—Headache—Doxorubicin—muscle cancer	0.00083	0.00164	CcSEcCtD
Loxapine—Nausea—Doxorubicin—muscle cancer	0.000787	0.00155	CcSEcCtD
